« Back to Medicines list

Lamictal 50mg Tablets

  • Name:

    Lamictal 50mg Tablets

  • Company:
    info
  • Active Ingredients:

    Lamotrigine

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/01/21

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/1/2021

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
Medicine Name Bexsero, suspension for injection in pre-filled syringe Active Ingredients Meningococcal group-B vaccine (rDNA, component, adsorbed)
Medicine Name Boostrix - Suspension for injection Active Ingredients Diphtheria, Tetanus and Pertussis vaccine
Medicine Name Cervarix Suspension for Injection Active Ingredients human papillomavirus vaccine
1 - 0 of 130 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 January 2021 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4: Addition of photosensitivity reaction warning
Section 4.8: Addition of photosensitivity reaction undesirable effect to the skin and subcutaneous tissue disorders under frequency uncommon
 

Updated on 18 January 2021 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 9 December 2020 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4. Update the wording on hypersensitivity syndrome.
Section 4.8 Removal of duplicate Hypersensitivity syndrome symptoms from the adverse event table
Section 4.8 Minor update – aseptic meningitis under nervous system disorders was moved from the bottom to the middle paragraph.
Section 4.8 Addition of the ADR Tubulointerstitial nephritis (TIN) that may occur in association with uveitis and involvement of the kidney as part of DRESS.
Section 4.8 Update to description of selected adverse reactions: Haematological abnormalities and lymphadenopathy and Rash.
Section 4.8 removal of duplicate statement regarding rash reported as part of hypersensitivity syndrome.
Section 4.8 Update to reporting of side effects details.

Updated on 9 December 2020 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 13 March 2020 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Updated on 13 March 2020 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4 - Addition of warning for sodium

Updated on 5 February 2020 SPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 6.5 - addition of child resisitant blister to the nature and contents of container

Updated on 5 November 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 5 November 2018 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

To update SmPC Section 4.4, 4.6, 4.8, PIL Section 2 & Section 4 in line with CMDh adopted PRAC recommendation. Inclusion of Brugada syndrome and haemophagocytic lymphohistiocytosis in take special care. Also a note to woman that are breastfeeding to observe if any symptoms are observed in the baby.

Updated on 13 July 2018 SPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

  • Update to SmPC Section 4.5 - Interaction with other medicinal products and other forms of interaction – Update wording on Lamictal and Locosomide/Perampanel interaction in the SmPC.
  • Update to SmPC Section 4.6 - Pregnancy and lactation – typographical mistake, removal of the word ‘therefore’

Updated on 26 February 2018 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 26 February 2018 SPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.5 - updated with the Lamotrigine and cytochrome P450 interactions. Hepatic drug metabolising replaced with cytochrome P450.

Updated on 3 November 2016 SPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.5 Interaction with other medicinal products and other forms of interaction - Update wording on OCT-2 inhibition in the SMPC.

Please note that the combined SPC for Lamictal Tablets will no longer be used. The SPC for Lamictal Tablets will now be individual SPC documents for each strength - SPC for 25mg, SPC for 50mg, SPC for 100mg and SPC for 200mg (4 individual SPCs in total).

Updated on 14 April 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 14 April 2016 PIL

Reasons for updating

  • Change to instructions about missed dose
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 18 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details
  • Change to improve clarity and readability

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 3 March 2015 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 22 October 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 15 May 2014 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 22 January 2014 PIL

Reasons for updating

  • Change to instructions about overdose

Updated on 23 September 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 12 September 2012 PIL

Reasons for updating

  • Change to side-effects

Updated on 6 December 2011 PIL

Reasons for updating

  • Change of contraindications

Updated on 13 December 2010 PIL

Reasons for updating

  • Change to drug interactions
  • Change to dosage and administration

Updated on 26 January 2010 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to dosage and administration

Updated on 27 November 2008 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 22 February 2007 PIL

Reasons for updating

  • Change of manufacturer

Updated on 6 December 2006 PIL

Reasons for updating

  • Change to information about pregnancy or lactation

Updated on 12 July 2006 PIL

Reasons for updating

  • Change of manufacturer
  • Change to warnings or special precautions for use

Updated on 31 January 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 11 January 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 26 August 2005 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 26 May 2005 PIL

Reasons for updating

  • New PIL for medicines.ie